Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.

@article{Stoitchkov2002MelanomaPA,
  title={Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.},
  author={Konstantin Stoitchkov and Sabine Letellier and J. P. Garnier and Bernard Bousquet and Nikolai Tsankov and Patrice Morel and Ghanem Ghanem and Thierry Le bricon},
  journal={Melanoma research},
  year={2002},
  volume={12 3},
  pages={255-62}
}
The challenge to find a reliable tumour marker for the management of melanoma patients still remains. In this study, the serum L-dopa/L-tyrosine ratio was compared with serum S100B as a reference marker. A total of 89 melanoma patients were sampled and staged according to the American Joint Committee on Cancer (AJCC) classification. Of these, 19 stage III and 28 stage IV patients were evaluated for disease progression at 1.5 years and 6 months post-sampling, respectively. Serum L-dopa and L… CONTINUE READING